Clinical Trial Protocol
Iranian Registry of Clinical Trials

09 Jun 2026

Evaluation of the protective effect of Curcuma Longa against cisplatin induced nephrotoxicity in patients with cancer

Protocol summary

Study aim
Evaluation of the protective effect of Curcuma Longa against cisplatin induced nephrotoxicity in patients with cancer

Design
Clinical trial with a control group, with parallel groups, one-way blind, randomized, on 30 patients (2 groups of 15 people). Patients are allocated randomly with simple sequential allocation in one of the two study groups by help of sealed envelope.

Settings and conduct
This study will be performed as a clinical trial in Kosar Hospital in Semnan. Patients are unaware of the intervention groups. Variables are measured before starting cisplatin treatment and also at 5 and 21 days after starting cisplatin treatment.

Participants/Inclusion and exclusion criteria
Inclusion criteria: Age 18-60 years; Confirmation of cancer by a specialist doctor; The disease should be such that the use of cisplatin as a treatment is approved by a specialist doctor. Exclusion criteria: The patient has a previous kidney disease (GFR is low from the beginning); Existence of underlying diseases such as diabetes, hypertension, etc. in the patient; Increased creatinine indicated for discontinuation of the drug.

Intervention groups
Intervention group: In addition to routine treatments, this group consumes one turmeric tablet of "Dineh Iran" company (Each tablet contains 450 mg of turmeric rhizome powder and 50 mg of turmeric extract, which is standardized based on 5.47 mg of curcumin) with lunch 3 days before the start of cisplatin treatment. Control group: This group only receives routine treatments.

Main outcome variables
Blood creatinine level; BUN(Blood Urea Nitrogen) level; Creatinine Clearance level.

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20151228025732N70**
Registration date: **2021-12-07, 1400/09/16**
Registration timing: **registered_while_recruiting**

Last update: **2021-12-07, 1400/09/16**
Update count: **0**

Registration date
2021-12-07, 1400/09/16

Registrant information

Name
Alireza Emadi

Name of organization / entity
Semnan University of Medical Sciences, Semnan, Iran

Country
Iran (Islamic Republic of)

Phone
+98 23 3345 1336

Email address
are20935@semums.ac.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2021-12-06, 1400/09/15

Expected recruitment end date
2022-02-04, 1400/11/15

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Evaluation of the protective effect of Curcuma Longa against cisplatin induced nephrotoxicity in patients with cancer

Public title
Evaluation of the protective effect of Curcuma Longa induced nephrotoxicity in patients with cancer

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:
Age 18-60 years Confirmation of cancer by a specialist doctor The disease should be such that the use of cisplatin as a treatment is approved by a specialist doctor

Exclusion criteria:
The patient has a previous kidney disease (GFR is low from the beginning) Existence of underlying diseases such as diabetes, hypertension, etc. in the patient Increased creatinine indicated for discontinuation of the drug

Age
From **18 years** old to **60 years** old

Gender
Both

Phase
N/A

Groups that have been masked

- Participant

Sample size
Target sample size: **30**

Randomization (investigator's opinion)
Randomized

Randomization description
Numbers 1 to 30 are written on paper and all of them are placed in sealed envelopes. Patients are then asked to select an envelope each. Patients whose number in the envelope is odd will be in the intervention group and patients whose number in the envelope is even will be in the control group.

Blinding (investigator's opinion)
Single blinded

Blinding description
Drug packaging is coded. So that the patients are unaware of the drug content packaging and intervention that they receive.

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ethics committee of Semnan University of Medical Sciences

Street address
Semnan University of Medical Sciences, Basij Blvd, Semnan

City
Semnan

Province
Semnan

Postal code
3514799442

Approval date
2020-10-27, 1399/08/06

Ethics committee reference number
IR.SEMUMS.REC.1399.218

Health conditions studied

1

Description of health condition studied
Cisplatin induced nephrotoxicity

ICD-10 code
N17.9

ICD-10 code description
Acute kidney failure, unspecified

Primary outcomes

1

Description
Blood creatinine level

Timepoint
Before starting treatment with Cisplatin and 5 and 21 days after starting treatment with Cisplatin

Method of measurement
Biorexfars Laboratory Diagnostic Kit

2

Description
BUN(Blood Urea Nitrogen) level

Timepoint
Before starting treatment with Cisplatin and 5 and 21 days after starting treatment with Cisplatin

Method of measurement
Biorexfars Laboratory Diagnostic Kit

3

Description
Creatinine Clearance level

Timepoint
Before starting treatment with Cisplatin and 5 and 21 days after starting treatment with Cisplatin

Method of measurement
Through Up-to-date software and using the CKD-EPI formula

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: In addition to routine treatments, this group consumes one turmeric tablet of "Dineh Iran" company (Each tablet contains 450 mg of turmeric rhizome powder and 50 mg of turmeric extract, which is standardized based on 5.47 mg of curcumin) with lunch 3 days before the start of cisplatin treatment.
Category
Treatment - Drugs

2

Description
Control group: This group only receives routine treatments
Category
Treatment - Other

Recruitment centers

1

Recruitment center
Name of recruitment center
Kowsar Hospital
Full name of responsible person
Seyed Ali Madani Lamraski
Street address
Street Amin, Semnan
City
Semnan
Province
Semnan
Postal code
3519899951
Phone
+98 23 3345 1336
Email
are20935@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Semnan University of Medical Sciences
Full name of responsible person
Parviz Kokhaei
Street address
Semnan University of Medical Sciences, Basij Blvd, Semnan.
City
Semnan
Province
Semnan
Postal code
3514799442
Phone
+98 23 3345 1336
Email
p_kokha@yahoo.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Semnan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Semnan University of Medical Sciences
Full name of responsible person
Mohammad Amir Sarabi
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Hematology
Street address
Street Amin, Semnan
City
Semnan
Province
Semnan
Postal code
3519899951
Phone
+98 23 3345 1336
Email
are20935@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Semnan University of Medical Sciences
Full name of responsible person
Mohammad Amir Sarabi
Position

Associate professor

Latest degree
Subspecialist

Other areas of specialty/work
Hematology

Street address
Street Amin, Semnan

City
Semnan

Province
Semnan

Postal code
3519899951

Phone
+98 23 3345 1336

Email
are20935@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Semnan University of Medical Sciences

Full name of responsible person
Mohammad Amir Sarabi

Position
Associate professor

Latest degree
Subspecialist

Other areas of specialty/work
Hematology

Street address
Street Amin, Semnan

City
Semnan

Province
Semnan

Postal code
3519899951

Phone
+98 23 3345 1336

Email
are20935@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available

Study Protocol
Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan
No - There is not a plan to make this available

Informed Consent Form
No - There is not a plan to make this available

Clinical Study Report
No - There is not a plan to make this available

Analytic Code
No - There is not a plan to make this available

Data Dictionary
No - There is not a plan to make this available